PFM
SRPT icon

Privium Fund Management’s Sarepta Therapeutics SRPT Stock Holding History

Privium Fund Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.45M Buy
136,500
+90,500
+197% +$1.71M 0.45% 33
2026
Q1 		$1M Buy
46,000
+3,000
+7% +$58.1K 0.21% 44
2025
Q4 		$925K Buy
+43,000
New +$906K 0.17% 43
2025
Q3 		– Sell
-39,400
Closed -$698K – 63
2025
Q2 		$698K Buy
+39,400
New +$1.68M 0.15% 41

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Privium Fund Management's SRPT Position: Q2 2026 in Review

Privium Fund Management increased its Sarepta Therapeutics (SRPT) stake by 197% in Q2 2026, buying an estimated $1.71M and bringing the position to 136,500 shares worth $2.45M. The position accounts for 0.45% of the portfolio, ranked #33.

Privium Fund Management first reported a position in SRPT in Q2 2025 and has held it in 4 quarters since. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Privium Fund Management held 136,500 shares of Sarepta Therapeutics worth $2.45M as of Q2 2026.
  • Privium Fund Management bought 90,500 Sarepta Therapeutics shares in Q2 2026, an estimated $1.71M.
  • Sarepta Therapeutics made up 0.45% of Privium Fund Management's portfolio in Q2 2026, its #33 holding.
  • Privium Fund Management first reported a position in Sarepta Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.